Category: ACN Newswire

SAN DIEGO, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI) was named the winner of two awards during Aviation Week's 21st annual Program Excellence Awards last week. GA-ASI's United Kingdom (UK) Protector Program was given the Special Projects Award, while its Japan COCO (Company-Owned, Company-Operated) Program won in the category of OEM System Sustainment."We're excited that these two important MQ-9B international programs have been recognized by Aviation Week," said GA-ASI CEO Linden Blue. "We're fortunate to have an incredible team of employees whose dedication and commitment to our customers is truly remarkable."MQ-9B is GA-ASI's most advanced Remotely Piloted Aircraft (RPA) system and includes the SkyGuardian® and SeaGuardian® models, as well as the UK's Protector RG Mk1.In 2025, GA-ASI achieved the first-ever Military Type Certificate (MTC) for the Royal Air Force's (RAF) Protector RG Mk1, passing a rigorous airworthiness assessment and verifying its safe operation without geographic restrictions. The global impact of the UK Protector MTC was recognized because it's a singular achievement that enables routine UAS operations in civil airspace from domestic RAF bases, drastically expanding its operational flexibility and reducing reliance on segregated ranges or overseas deployments. But more importantly, it serves as a proof of concept for future unmanned systems seeking full integration into regulated airspace and sets a precedent for allied and NATO forces worldwide.In Japan, the MQ-9B SeaGuardian COCO Program has proven so successful that the aircraft that had been leased to Japan have now been converted to sales, with additional MQ-9Bs now on order. SeaGuardian has been used by Japan to deliver real-time situational awareness anywhere in the maritime domain - day or night. It is also the first RPA in its class to enable real-time search and patrol above and below the ocean's surface.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, MQ-9B SkyGuardian®/SeaGuardian®, XQ-67A, and YFQ-42A. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

加州聖地牙哥, 2026年3月25日 - (亞太商訊 via SeaPRwire.com) - 通用原子航空系統公司（GA-ASI）在上週《航空週刊》第 21 屆年度「計畫卓越獎」頒獎典禮中，榮獲兩項大獎。GA-ASI的英國「守護者」計畫榮獲「特別專案獎」，而其日本COCO（公司擁有、公司營運）計畫則在「原始設備製造商系統維運」類別中勝出。「我們很高興這兩個重要的 MQ-9B 國際計畫獲得《航空週刊》的肯定，」GA-ASI 執行長林登·布魯表示。「我們很幸運擁有這樣一支卓越的員工團隊，他們對客戶的奉獻精神與承諾實在令人讚嘆。」MQ-9B 是 GA-ASI 最先進的遙控飛行器（RPA）系統，包含 SkyGuardian® 與 SeaGuardian® 型號，以及英國的 Protector RG Mk1。2025年，GA-ASI 為英國皇家空軍（RAF）的「守護者」RG Mk1 無人機取得了首張軍用型號證書（MTC），該機通過了嚴格的適航評估，並驗證了其在無地理限制情況下的安全運作能力。英國「守護者」MTC的全球影響力備受認可，因為這是一項獨特的成就，使無人機系統能夠從英國皇家空軍國內基地出發，在民用空域進行常規運作，大幅提升其作戰靈活性，並減少對隔離飛行區或海外部署的依賴。但更重要的是，這為未來尋求全面整合至受管制空域的無人系統提供了概念驗證，並為全球盟軍及北約部隊樹立了先例。在日本，MQ-9B「海衛士」（SeaGuardian）COCO計畫成效卓著，原先租賃給日本的機體現已轉為銷售，且已追加訂購更多MQ-9B。日本利用「海衛士」在海上領域的任何地點——無論晝夜——提供即時戰況感知。它也是同級別中首款能夠在海面以上及以下進行即時搜索與巡邏的無人機。關於 GA-ASI通用原子航空系統公司（General Atomics Aeronautical Systems, Inc.）是全球首屈一指的無人機系統（UAS）製造商。「捕食者®」（Predator®）系列無人機系統累積飛行時數已超過 900 萬小時，服役時間逾 30 年，產品陣容包含 MQ-9A「死神®」（Reaper®）、MQ-1C「灰鷹®」（Gray Eagle®）、MQ-20「復仇者®」（Avenger®）、MQ-9B「天衛®」（SkyGuardian®）/「海衛®」（SeaGuardian®）、XQ-67A 及 YFQ-42A。本公司致力於提供長航時、多任務解決方案，以實現持續的戰場態勢感知與快速打擊能力。欲了解更多資訊，請造訪 www.ga-asi.com 。Avenger、EagleEye、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 及 SkyGuardian 均為通用原子航空系統公司（General Atomics Aeronautical Systems, Inc.）於美國及／或其他國家註冊的商標。GA-ASI 媒體關係通用原子航空系統公司 ASI-MediaRelations@ga-asi.com (858) 524-8101消息來源：通用原子航空系統公司 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Reno, Nevada--(ACN Newswire via SeaPRwire.com - March 24, 2026) - Scandium Mining Corp. (TSXV: SCY) (OTC PINK: SCYYF) ("Scandium International" or the "Company"), a leader in the advancement of critical mineral resources, is pleased to announce the release of its updated investor presentation, now available to investors and stakeholders. The new presentation can be accessed here: Investor PresentationThe new investor presentation provides updated information on the Nyngan project in New South Wales, Australia, which is now fully shovel-ready. This project is one of only two primary scandium deposits at this advanced stage in the western world, positioning the company at the forefront of the emerging scandium market.Scandium is an essential element in high-performance applications, including aerospace, defense, and clean power generation. Its unique properties-such as exceptional strength-to-weight ratio and improved corrosion resistance when alloyed with aluminum-make it indispensable for the next generation of lightweight, durable materials. As demand grows for advanced technologies and sustainable solutions, scandium's role is increasingly being recognized by innovative manufacturers and governments alike."We're excited to share this comprehensive update on our progress," said Peter Evensen, CEO of Scandium International. "With our mining license now valid over the entire resource, the project is shovel-ready and we are uniquely positioned to supply scandium at scale to industries that are shaping the future."To view the latest presentation and learn more about Scandium Mining's plans, visit: Scandium International Mining CorporationAbout Scandium MiningScandium Mining is dedicated to unlocking the potential of scandium for high-impact industries worldwide. With its shovel-ready primary scandium deposit, the company is committed to responsible development and long-term value creation.For inquiries to Scandium International Mining Corp, please contact: Peter Evensen, President and CEOTel: (775) 355-9500Harry de Jonge (Controller)Tel: (702) 703-0178Email: info@scandiummining.comCautionary Note Regarding Forward-Looking InformationThis news release includes certain information that may be deemed "forward-looking information". Forward-looking information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "believe", "continue", "plans" or similar terminology, or negative connotations thereof. All information in this release, other than information of historical facts, general future plans and objectives for the Company and the Nyngan Scandium Project, are forward-looking information that involve various risks and uncertainties. Although the Company believes that the expectations expressed in such forward-looking information are based on reasonable assumptions, such expectations are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking information.For more information on the Company and the key assumptions, risks and challenges with respect to the forward-looking information discussed herein, and about our business in general, investors should review the Company's most recently filed annual information form, and other continuous disclosure filings which are available at www.scandiummining.com Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289611 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 國際指數評級機構明晟 MSCI日前公佈了年度 ESG（環境、社會及企業管治） 評級報告，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」或「公司」，股份代號：1788.HK））評級從「A」級躍升至最高「AAA」級。公司在負責任投資、可持續融資業務、人力資本發展、數據安全及企業行為等領域表現尤為突出，處於全球同業領先水準。這一重要突破標誌著公司在可持續發展領域的持續努力與卓越表現獲得國際權威機構的高度認可。根據MSCI ESG評級的最新評估，國泰君安國際在多個關鍵議題上表現優異，成為本次評級上調的主要驅動因素：在負責任投資方面，得益於可持續發展指標的優化調整，公司得分顯著提升。公司始終致力於可持續發展，將負責任的投資理念全面融入投資組合管理，在投資流程中系統性地納入ESG因素，以此在傳統財務分析基礎上，進一步增強對潛在投資的ESG表現評估，從而推動被投資方的綠色轉型。在可持續融資業務方面，國泰君安國際在投資銀行業務中積極開展可持續發展盡職調查，並通過為企業客戶承銷及發行綠色債券，持續推動綠色金融發展，降低與業務相關的環境風險，展現了其在綠色投融資領域的責任擔當與專業能力。在人力資本發展方面，由於績效評估方法論的改進以及公司實踐的持續完善，得分亦實現增長。公司秉持「人才是第一資源」的經營理念，並奉行「以人為本、協同協作」的原則，視員工為本集團最有價值的資產。通過提升薪酬待遇、提供員工福利、創造成長機會，持續加強人才招募和留任策略，進一步鞏固公司作為優選雇主的地位，推動長期可持續發展。在數據安全領域，MSCI報告指出，國泰君安國際主要運營於香港這一隱私保護法規較為嚴格的地區，公司在數據安全實踐方面保持行業領先，通過制定覆蓋全集團的隱私政策，並引入外部獨立IT安全審計，公司有效構築了網路安全風險防線。國泰君安國際此次MSCI ESG評級躍升至AAA級，充分體現了公司在環境、社會及管治方面的長期投入與系統化建設成果。作為國泰海通集團的重要國際業務平台，公司將繼續秉持可持續發展理念，深化ESG治理實踐，積極履行社會責任，為股東、客戶及社會創造長期可持續價值。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）,是中國證券公司國際化的先行者和引領者，公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港為業務基地，並在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，為客戶境外資產配置提供高品質、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）為中國資本市場長期、持續、全面領先的綜合金融服務商。更多關於國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - Baguio Green Group Limited (‘‘Baguio’’ or the ‘‘Group’’, Stock Code: 01397.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the Year, the Group’s revenue amounted to approximately HK$2,424.6 million, representing a decrease of approximately 6.9% as compared to the same period last year. Profit for the Year amounted to approximately HK$97.1 million, representing an increase of approximately 72.0% as compared to the same period last year. The Board recommends the payment of a final dividend for the Year at HK7.0 cents per share.Business Overview and ProspectsDuring the Year, revenue from cleaning services as the Group’s core business amounted to approximately HK$1,896.5 million, accounting for approximately 78.2% of the Group’s total revenue. The Group’s cleaning services cover various scenarios, including for Government streets, markets, police stations, fire stations, leisure venues, hospitals and clinics. In addition, the Group provides cleaning services for numerous different places such as universities, large exhibition centers, Hong Kong International Airport, housing estates and private institutions.During the Year, the Group successfully awarded a 3-year contract from the Marine Department of the Government for approximately HK$150 million for the provision of “Marine Refuse Cleansing and Disposal Services in the Eastern waters of Hong Kong”. This contract marks a significant milestone for Baguio, as it represents a strategic expansion of its service portfolio from land to sea, further strengthening its leading position in Hong Kong’s integrated environmental services market. Under the contract, Baguio delivers comprehensive marine refuse cleansing and ship refuse collection services in the Eastern waters of Hong Kong starting from 1 October 2025 including, but not limited to: Victoria Harbour, Central, Sheung Wan, Causeway Bay, Tsim Sha Tsui, Yau Ma Tei, Cheung Sha Wan, Shau Kei Wan, Kwun Tong, Sai Kung, Tolo Harbour and Tai Po. Winning this contract signifies strong market recognition of Baguio’s outstanding performance over the past 46 years. The Group will seamlessly extend its professional standards and operational efficiency in land-based waste management to the marine environment, striving to safeguard Hong Kong’s valuable marine ecosystem and present a cleaner, more beautiful Victoria Harbour to both residents and tourists.Waste management and recycling business recorded revenue of approximately HK$277.8 million, accounting for approximately 11.5% of the Group’s total revenue. The gross profit margin of the waste management and recycling business increased from 11.6% for the same period last year to 15.0%, driving the gross profit of this business up by approximately 25.2% to approximately HK$41.9 million, mainly due to the Government’s proactive promotion of recycling and the substantial expansion of the network of recycling spots, including those for food waste, which facilitated public participation and effectively stimulated collection, and the contribution from the green technology business.The Group continued to provide Government-related waste collection services to five districts, serving a population of approximately 1.6 million.In terms of recycling, the Group is contracted by the Environmental Protection Department (“EPD”) of the Government to provide collection services for thousands of recycling spots (including plastics, glass bottles, metals, waste paper and food waste) across Hong Kong. During the Year, the Group provided collection services for recycling bins in public places and schools. Baguio also provides collection services for Recycling Stations of “GREEN@COMMUNITY”, recycling stores and smart recycling machines, and other institutions in Hong Kong. In addition, Baguio also provides the Government with glass bottles collection and management services and food waste collection services in several districts in Hong Kong, and is one of the market leaders. In addition, during the Year, the Group was successfully awarded two 35-month contracts from the EPD, with a total value of approximately HK$43 million. During the Year, the Group was responsible for operating the “GREEN@Tai Wo” and “GREEN@Po Lam” recycling stores, and collaborated with nearby buildings, organizations, and community stakeholders to establish and operate fixed and mobile recycling spots for waste collection, provide community recycling support to facilitate citizens, and promote and educate the public on waste sorting and recycling in the community to strengthen citizens’ recycling habits.As a leading environmental services provider in Hong Kong, the Group provides integrated environmental management solutions including waste management, smart recycling and professional landscaping services to Kai Tak Sports Park, which hosts major sports events and concerts. With excellent environmental protection technologies and experience in operating large-scale international venues, the Group has fully demonstrated its strength in undertaking large-scale international programmes and delivering high-quality services. During the Year, the Group also provided waste recycling services for various Lunar New Year fairs across Hong Kong Island, Kowloon and the New Territories.Regarding green technology business, the Group won a new contract in relation to the development and supply of a new generation of solar-powered compacting refuse bins to the Government. This innovative product is designed with an auto-sensing inlet and indicator lights, and under its sealed design, it is equipped with devices for ventilation, lighting, and deodorization. Meanwhile, it is equipped with a big data platform and wireless technology to monitor data in real time, enabling effective tracking of the status of waste collection points, strategic deployment of resources, optimization of operational efficiency, and enhanced planning for future initiatives. Furthermore, the solar-powered compacting refuse bins adopt solar panels and rely on renewable energy, which significantly reduces carbon emissions. They can be flexibly deployed in various scenarios, suitable for remote areas where there are no refuse collection points. This product is expected to be gradually launched into the market in 2026.The Group seizes the opportunity of smart city development and has been committed to expanding its market share of smart recycling in recent years. Currently, Baguio’s smart recycling products, such as smart recycling machines, smart food waste recycling machines, and smart balances, have been deployed in different places across Hong Kong, including Government venues and schools, private housing estates, commercial buildings, theme parks, large-scale exhibition venues, and sports stadiums. These products provide the public with convenient recycling services 24 hours a day and help increase Hong Kong’s overall recycling volume.In partnership with Jardine Engineering Corporation Limited, the Pilot Biochar Production Plant at the EcoPark in Tuen Mun converts yard waste into high-quality biochar with pyrolysis technology for various applications, the production plant effectively “turns waste into useful resources”.As for the landscaping business, the Group provides landscaping services for a wide range of clients, including large private residences, Government premises, schools, shopping malls, hotels, Hong Kong Housing Authority, Hospital Authority, Hong Kong Jockey Club, Hong Kong Science Park, the University of Hong Kong, Hong Kong University of Science and Technology, Hong Kong Wetland Park, as well as 33 sports turf venues under the Leisure and Cultural Services Department, etc. During the Year, the Group provided landscaping services for Kai Tak Sports Park, Hong Kong International Airport, Hong Kong-Shenzhen Innovation and Technology Park, Nano Parks, the Tung Chung New Town Extension (West), Hung Shui Kiu/Ha Tsuen New Development Area and the ventilation building at the eastern portal of the Tseung Kwan O – Lam Tin Tunnel.For pest management business, the Group provided pest management services for venues in the Tsuen Wan District during the Year. In addition, the Group provided pest and rodent control services for hospitals, clinics and the headquarters of the Kowloon East, Kowloon Central and Kowloon West Clusters under the Hospital Authority. The Group also continued to provide termite control and monitoring services for 24 temples under the Chinese Temples Committee.The Promotion of Recycling and Proper Disposal of Products (Miscellaneous Amendments) Bill 2025 submitted by the Government was passed by the Legislative Council during the Year. This bill establishes a common legal framework for producer responsibility scheme applicable to different products. Under this framework, the Government plans to submit the producer responsibility scheme on plastic beverage containers and beverage cartons in 2026. The scheme encourages citizens to return used containers for recycling to earn rebate, which will help significantly increase the recycling rate. Benefiting from the scheme, Baguio’s recycling volume is expected to be directly driven up, providing attractive returns for the Group’s long-term investments in recycling services and competitive barriers.The Government is actively developing the Northern Metropolis. Four new development areas include Kwu Tung North/ Fanling North, Hung Shui Kiu/Ha Tsuen, Yuen Long South, and San Tin Technopole are under construction. The Government has resumed more than 400 hectares of private land within these four new development areas, completed land levelling for 80 hectares, and is progressively handing over these lands to relevant departments for building road and railway infrastructure, public and private housing, schools, public markets, ecological conservation, as well as development of innovation and technology industry. The Group believes that this will bring opportunities for many of its core businesses.Looking forward, the Group will continue to increase the market share of its core businesses and proactively engage in expansion in Hong Kong and beyond. Meanwhile, in line with the development of the Group, it will actively explore potential mergers and acquisitions, joint ventures or new business projects to accelerate future business growth and deliver substantial and long-term returns to shareholders.For details of the Group's 2025 annual results announcement, please visit the following website: https://www.baguio.com.hk/en/investor/notices/About Baguio Green GroupEstablished in 1980, Baguio Green Group (Stock code: 01397.HK) is one of Hong Kong’s largest integrated environmental management solution providers. It provides a full spectrum of professional services including professional cleaning, waste collection & recycling, waste management, green technology, green products, horticulture & landscaping, and pest control. The Group delivers innovative environmental solutions using the latest technologies to serve a wide range of customers in various sectors including Government departments, statutory organizations and multinational corporations. Fully committed to ESG, the Group works relentlessly to advance sustainable development and create a cleaner, greener, healthier city for a greener tomorrow. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 今日，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」或「公司」，股份代號：1788.HK）作為聯席保薦人、保薦人兼整體協調人、聯席全球協調人、聯席帳簿管理人及聯席牽頭經辦人，成功助力浙江凱樂士科技集團股份有限公司（「凱樂士科技」，股份代號：2729. HK）在香港聯交所主板上市，充分彰顯國泰海通集團在跨境資本運作、高效整合資源、服務專精特新科技企業方面的綜合實力。（國泰君安國際投行團隊出席上市儀式）作為綜合智能場內物流機器人龍頭企業，凱樂士科技業務橫跨29個不同行業及境內外19個國家及地區，兩次獲得國家工業和信息化部授予的國家級專精特新「小巨人」企業認證。本次發行最終定價為每股16.66港元，總發售股數達3,679.80萬股，發行規模6.13億港元。國際配售和香港公開發售錄得踴躍認購，國際配售認購倍數達3.37倍，香港公開發售認購倍數達2153.26倍，充分展現了國際資本對中國高端製造的堅定信心，也生動展示了國泰海通服務科技創新與產業升級的成果。凱樂士科技的成功上市，是繼龍旗科技（股票代碼：9611.HK）、愛芯元智（股票代碼：0600.HK）後，國泰君安國際在今年完成的第三個科技創新領域保薦項目，彰顯了國泰君安國際作為一流投行的綜合實力與卓越執行力。依託與總部國泰海通的協同優勢，公司不僅展現出在複雜跨境資本運作中高效整合資源、精准把握市場視窗的專業能力，更憑藉對「專精特新」及高端製造領域的深刻洞察，持續為中國科技企業走向國際資本市場搭建堅實橋樑。展望未來，國泰君安國際將繼續秉持金融服務實體經濟的初心，以更高水準的綜合金融服務，助力更多中國優質企業揚帆遠航，在全球資本市場書寫新的篇章。關於凱樂士科技凱樂士科技是領先綜合智能場內物流機器人提供商，擁有廣泛的機器人技術能力及多元化的自主研發機器人產品組合，涵蓋廣泛採用的高度和有效載荷規格的核心場內物流功能。凱樂士科技在極窄巷道自主移動機器人及四向穿梭車等主要類別的尖端智能場內物流機器人的出貨量處於領先地位。凱樂士業務橫跨29個不同行業及境內外19個國家及地區，並且成功交付實施了超過1,600個項目，其下游客戶涵蓋各行各業的領先企業，包括醫藥、3C電子產品、新能源及汽車行業的領先企業。憑藉立足中國，全球領先的長期戰略，凱樂士科技將持續受益於中國企業出海的浪潮，成為中國企業出海的關鍵場內物流基礎設施推動者。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）,是中國證券公司國際化的先行者和引領者，公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港為業務基地，並在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，為客戶境外資產配置提供高品質、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）為中國資本市場長期、持續、全面領先的綜合金融服務商。更多關於國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛羅里達州西棕櫚灘, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - USPA Global 的娛樂子公司 Global Polo 延續與 ESPN 的歷史性合作關係，持續推廣馬球運動，其影響力已擴及全球數百萬家庭。這項里程碑式的合作包含：傳奇ESPN解說員克里斯·福勒將首度主持3月29日的USPA金盃®決賽，並於4月26日第二度主持美國公開馬球錦標賽®決賽。賽事將於佛羅里達州棕櫚灘縣的USPA國家馬球中心舉行，屆時他將與資深播報員肯尼·萊斯及馬球名人堂成員亞當·斯諾共同主持。Legendary ESPN Commentator, Chris Fowler, at the USPA National Polo Center in Palm Beach County, FloridaPhoto Credit: Alex Pacheco「我有幸報導過體育界許多最具標誌性的賽事，而讓我持續被馬球運動吸引的，正是馬球選手與馬匹之間獨特的夥伴關係，以及頂級賽事中那令人屏息的速度與激烈程度，」福勒表示。「能同時主持美國馬球協會金盃賽與美國公開馬球錦標賽，讓我得以將這項美麗運動的活力與獨特性，分享給更廣大的ESPN觀眾。」「親眼見證這些世界級運動員與他們的馬匹夥伴，在如此節奏明快且講求策略的比賽中競技，是無與倫比的體驗，」福勒補充道。美國馬球協會金盃（USPA Gold Cup）始於1974年，是美國馬球界僅次於美國公開馬球錦標賽（U.S. Open Polo Championship）的第二大賽事，而後者則始於1904年。今年的賽事將於3月4日至29日舉行，屆時將有10支頂尖隊伍在最高水平的競技中一較高下。而備受矚目的美國公開馬球錦標賽將於4月1日至26日舉行，該賽事被公認為眾多世界頂尖球員與馬匹的展示舞台，至今仍是全球最具聲望的馬球賽事之一。自2004年移師佛羅里達州棕櫚灘郡以來，這兩項賽事便一直接連舉行。這些備受矚目的馬球賽事將於佛羅里達州威靈頓的美國馬球協會國家馬球中心（NPC）內，美國馬球協會第一球場舉行。四月初的美國馬球協會金盃（USPA Gold Cup）決賽，以及隨後於五月舉行的美國公開馬球錦標賽（U.S. Open Polo Championship）決賽，都將透過ESPN2等多個ESPN平台進行轉播。具體播出時間請查閱當地節目表。「我們與ESPN的長期合作關係，持續提升馬球運動、U.S. Polo Assn.品牌及其背後的全球影響力，」USPA Global總裁兼執行長J. Michael Prince表示。該公司負責管理市值數十億美元的全球運動品牌U.S. Polo Assn. 「克里斯·福勒（Chris Fowler）的回歸，以及他將同時主持USPA金盃賽與美國公開馬球錦標賽的擴展參與，進一步強化了這些世界級賽事在全球觀眾心中的熱度與能見度。」「在ESPN的支持下，馬球運動持續吸引著全球球迷的關注，」普林斯補充道。除了現場賽事轉播外，ESPN 平台還將播出由 Global Polo 製作、兩度獲獎的節目《Breakaway：U.S. Polo Assn. 呈獻》的新集數。觀眾可透過 Global Polo 的 YouTube 頻道收看獨家幕後花絮、球員專訪及錦標賽精華片段，其中包含與 USPA 金盃賽及美國公開馬球錦標賽轉播相關的特別報導。「美國馬球協會（USPA）很高興看到這項運動透過與ESPN的合作關係持續發展，」美國馬球協會（USPA）主席史都華·阿姆斯壯表示。「USPA金盃賽與美國公開馬球錦標賽代表著美國賽季中，在USPA國家馬球中心舉行的最高水準賽事，而ESPN所提供的更高曝光度，更凸顯了定義我們這項運動的運動精神、奉獻精神與傳統。」欲獲取最新資訊與即時快訊，請至 globalpolo.com 訂閱《Polo Insider》電子報，並造訪 uspolo.org。關於 ESPNESPN 作為全球領先的多平台體育娛樂品牌，旗下擁有七個美國電視頻道、頂尖的體育應用程式、直接面向消費者的 ESPN+ 服務、領先的社交與數位平台、ESPN.com、ESPN Audio，以及遍及全球各大洲的業務據點等。關於 U.S. Polo Assn. 與 USPA GlobalU.S. Polo Assn. 是美國馬球協會（USPA）的官方運動品牌。USPA 成立於 1890 年，是美國規模最大的馬球俱樂部與馬球選手組織。憑藉數十億美元的全球業務規模，以及透過超過 1,200 家 U.S. Polo Assn. 實體門市及數千個其他銷售據點的全球分銷網絡，U.S. Polo Assn. 為全球 190 多個國家的男女及兒童提供服飾、配件與鞋類產品。該品牌贊助全球各大馬球賽事，包括每年於棕櫚灘的 NPC 舉辦的「美國公開馬球錦標賽®」（U.S. Open Polo Championship®），此為美國首屈一指的馬球錦標賽。透過與美國 ESPN、歐洲 TNT 和 Eurosport 以及印度 Star Sports 的歷史性合作協議，由 U.S. Polo Assn. 贊助的多項世界頂級馬球錦標賽現已透過電視轉播，讓全球數百萬體育迷首次得以欣賞這項令人振奮的運動。根據《License Global》的報導，U.S. Polo Assn. 一直與 NFL、PGA 巡迴賽和一級方程式賽車並列為全球頂尖的運動授權商之一。此外，這個受運動啟發的品牌因全球業務拓展及體育內容而屢獲國際獎項肯定。憑藉其作為全球品牌的巨大成功，U.S. Polo Assn. 曾獲《富比世》、《財星》、《現代零售》及《GQ》等媒體報導，並登上雅虎財經與彭博社等全球眾多知名媒體平台。欲了解更多資訊，請造訪 uspoloassnglobal.com 並追蹤 @uspoloassn。USPA Global 是美國馬球協會（USPA）的子公司，負責管理市值數十億美元的運動品牌 U.S. Polo Assn.。USPA Global 同時管理其子公司 Global Polo，該公司是全球馬球運動內容的領導者。欲了解更多資訊，請造訪 globalpolo.com 或 YouTube 上的 Global Polo 頻道。關於美國馬球協會® (USPA)美國馬球協會® 的成立宗旨在於推廣馬球運動；協調其會員俱樂部及註冊球員的活動；籌辦並監督馬球錦標賽、競賽及比賽；並為相關賽事制定規則、讓分制度及賽事條件。其核心目標在於提升這項運動的水平，並促進人類與馬匹參與者的安全與福祉。USPA 成立於 1890 年，是北美地區規模最大的馬球自願性體育組織。USPA 目前擁有超過 200 家會員俱樂部及 5,000 多名註冊球員會員。該協會每年頒發獎項並監督由其會員俱樂部主辦的約 50 場全國性錦標賽。如需更多資訊，請造訪 uspolo.org。如需更多資訊，請聯絡：香農·斯蒂爾森（Shannon Stilson）－體育行銷與媒體副總裁 電話 +001.561.227.6994 － 電子郵件：sstilson@uspagl.com史黛西·科瓦爾斯基（Stacey Kovalsky）－全球公關與傳播副總裁 電話 +001.954.673.1331 - 電子郵件：skovalsky@uspagl.com克里斯汀·卡爾卡尼奧（Christine Calcagno） - ESPN 傳播部資深公關專員 電話 +001.959.216.8036 - 電子郵件：christine.b.calcagno@espn.com消息來源：USPA Global Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - Global Polo, the entertainment subsidiary of USPA Global, continues its historic relationship with ESPN to showcase the sport of polo, which has expanded its reach to millions of households worldwide. The landmark relationship includes legendary ESPN commentator Chris Fowler hosting the USPA Gold Cup® Final on Mar. 29 for the first time, and the U.S. Open Polo Championship® Final on Apr. 26 for the second year, at the USPA National Polo Center in Palm Beach County, Florida, alongside veteran broadcasters Kenny Rice and Polo Hall-of-Famer Adam Snow.Legendary ESPN Commentator, Chris Fowler, at the USPA National Polo Center in Palm Beach County, FloridaPhoto Credit: Alex Pacheco"I've had the privilege of covering some of the most iconic events in sports, and what continues to draw me back to the sport of polo is the unique partnership between the polo player and polo pony, as well as the speed and intensity of competition at the highest level," said Fowler. "Hosting both the USPA Gold Cup and the U.S. Open Polo Championship allows me to share the energy and uniqueness of this beautiful sport with a broader ESPN audience.""There's nothing quite like seeing these world-class athletes and their equine partners compete in such a fast-paced, strategic game," Fowler added.The USPA Gold Cup, first played in 1974, is the second most important tournament in American polo, right next to the U.S. Open Polo Championship, which was first played in 1904. This year's competition will feature 10 elite teams competing at the highest level of the sport from March 4 - 29. The prestigious U.S. Open Polo Championship, played April 1 - 26, is widely recognized as a showcase for many of the world's top players and equine athletes and remains one of the most prestigious polo tournaments globally. Both tournaments have been played back-to-back since they arrived in Palm Beach County, Florida, in 2004. These highly rated polo competitions take place on the U.S. Polo Assn. Stadium Field One at the USPA National Polo Center (NPC) in Wellington, Florida.Coverage of the USPA Gold Cup final in early April, followed by the U.S. Open Polo Championship final match in May, will be available on multiple ESPN platforms, including ESPN2. Check your local listings for specific airtimes."Our long-term relationship with ESPN continues to elevate the sport of polo, the U.S. Polo Assn. brand, and the global momentum behind it," said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar global sport brand, U.S. Polo Assn. "Chris Fowler's return and expanded presence hosting both the USPA Gold Cup and the U.S. Open Polo Championship further strengthens the momentum and visibility of these world-class tournaments to a global audience.""Supported by ESPN, the sport of polo continues to garner interest from fans around the world," added Prince.Beyond live game coverage, ESPN platforms also feature new episodes of the two-time award-winning show, Breakaway: Presented by U.S. Polo Assn. produced by Global Polo. Viewers can follow exclusive behind-the-scenes coverage, player features, and championship highlights on Global Polo's YouTube channel, including special coverage tied to the USPA Gold Cup and the U.S. Open Polo Championship broadcasts."The United States Polo Association is delighted to see the continued growth of the sport through our relationship with ESPN," said Stewart Armstrong, Chairman of the United States Polo Association (USPA). "The USPA Gold Cup and the U.S. Open Polo Championship represent the highest level of competition at the USPA National Polo Center for the American season, and the increased visibility provided by ESPN underscores the athleticism, dedication, and tradition that define our sport."For the most up-to-date information and breaking news, sign up for the Polo Insider newsletter at globalpolo.com and visit uspolo.org.About ESPNESPN, the world's leading multiplatform sports entertainment brand, features seven U.S. television networks, the leading sports app, direct-to-consumer ESPN+, leading social and digital platforms, ESPN.com, ESPN Audio, endeavors on every continent around the world, and more.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sport content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.About the United States Polo Association® (USPA)The United States Polo Association® is organized and exists for the purposes of promoting the game of polo; coordinating the activities of its member clubs and registered player members; arranging and supervising polo tournaments, competitions, and games; and providing rules, handicaps, and tournament conditions for those events. Its overarching goals are improving the sport and promoting the safety and welfare of its human and equine participants. Founded in 1890, the USPA is the largest voluntary sports organization in North America for the sport of polo. The USPA is currently made up of more than 200 member clubs and over 5,000 registered player members. It annually awards and oversees roughly 50 national tournaments hosted by its member clubs. For more information, please visit uspolo.org.For Additional Information, Contact:Shannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.comStacey Kovalsky - VP, Global PR and CommunicationsPhone +001.954.673.1331 - E-mail: skovalsky@uspagl.comChristine Calcagno - Sr. Publicist, ESPN CommunicationsPhone +001.959.216.8036 - E-mail: christine.b.calcagno@espn.comSOURCE: USPA Global Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 中國抗體製藥有限公司（「中國抗體」或「公司」，連同旗下附屬公司統稱「集團」，股份代號：03681.HK）欣然公布截至2025年12月31日止年度（「年內」）的全年業績。年內，公司虧損由截至2024年12月31日止年度的人民幣1.85億元减少人民幣0.80億元至約人民幣1.05億元，主要得益于公司聚焦SM17 1b期臨床、劑型橋接研究及2期臨床籌備，研發成本較2024年大規模臨床研究有所下降。截至2025年12月31日，公司可動用資金總額約人民幣3.52億元，較上年同期的人民幣1.41億元顯著增長。年內，集團獲得睿遠、富國、易方達等多家知名機構投資者支持，公司完成兩輪股份配售，合計募集所得款項淨額約4.93億港元，帶動融資活動所得現金流淨額達人民幣3.29億元，爲後續研發及臨床推進提供了充足資金支持。核心産品SM17取得多項突破性進展SM17是全球首創（First-in-Class）的靶向IL-25受體的人源化單抗，通過靶向II型免疫核心「警戒素（Alarmin）」分子白細胞介素25（IL-25）受體，調節II型炎症反應。SM17具有治療特應性皮炎（AD）、炎症性腸病（IBD）、哮喘、慢性鼻竇炎伴鼻息肉（CRSwNP）及特發性肺纖維化（IPF）的潜力。在特應性皮炎（AD）領域，SM17精准作用于II型免疫反應的上游，通過阻斷被稱作「警報素「的關鍵細胞因子IL-25，從源頭上抑制導致AD的炎症級聯反應。當前，已獲批上市的AD療法（包括生物製劑）雖然可以大大改善患者的濕疹面積和嚴重程度指數以及生活質量。然而目前在研在售藥物無法同時滿足快速起效止癢，皮損恢復，同時具備良好安全性的臨床需求，市場尚存在巨大空間。SM17的創新之處在于，它通過靶向Th2炎性細胞因子通路上游（如IL-25受體），從而對下游信號通路的致病因子産生抑制效果，且在臨床前研究中展現出快速止癢、顯著修復皮損以及良好安全性的潜力，直擊現有療法痛點。2025年4月，SM17在中國治療中重度特應性皮炎的1b期研究中，取得了令人鼓舞的積極結果：揭盲後的12周頂線數據顯示，高劑量組的91.7%的患者實現瘙癢緩解指標（NRS-4），75%達到皮損恢復(EASI75)指標，41.7%達到完全或近乎完全清除AD症狀指標（IGA 0/1）。該結果顯著優于IL4/IL-13類單抗藥物且安全性與耐受性顯著優于Janus激酶抑制劑（JAK抑制劑），這使得SM17有望成爲一款可同時實現快速止癢、皮膚損傷修復，且安全性表現優异的同類首創及同類最優療法。SM17的研究成果已在多家國際頂級期刊發表。預計最早在2026年年中進入AD的2期臨床試驗。此外，SM17持續拓展出多個新的適應症，于本年度第二季度，SM17的適應症拓展進一步取得突破性進展。2025年12月11日，SM17用于治療IBD的新藥研究申請（「IND」）已提交予中國國家藥品監督管理局（「中國國家藥監局」）藥品審評中心（「藥品審評中心」），幷已獲受理，且IND隨後于2026年2月獲批。此次IND的提交，代表著SM17治療範圍從AD拓展至IBD的重要里程碑，涵蓋克羅恩病（「CD」）及潰瘍性結腸炎（「UC」）等慢性、衰竭性疾病，這些疾病存在顯著未滿足的醫療需求。于2025年10月，首組健康受試者已在中國給藥途徑轉換之1期橋接臨床研究中給藥。截至2025年12月31日，合共三十名健康受試者已入組且對全部健康受試者之隨訪于2026年2月完成。該橋接研究預期于2026年第二季度前完成。該研究數據將用作支持IBD適應症的進展直接推進2期臨床開發。早期在研管線布局提供持續創新動力在早期在研管線方面，公司持續取得積極進展。2025年6月合作夥伴雲頂新耀公布了EVER001（中國抗體SN1011）用于治療原發性膜性腎病（PMN）的1b/2a期臨床試驗的積極結果，進一步提升了管線的商業化價值。同時，公司多項早期研發項目穩步推進。其中，抗CGC抗體是一款內部開發的全球首創人源化抗γc抗體。動物研究顯示，該抗體可能透過調節免疫細胞的擴增、自身反應性及組織浸潤，成爲治療白癜風、斑禿，甚至其他自身免疫性疾病的潜在治療藥物。目前正在針對該抗體進行CMC優化及毒理學研究，幷計劃最早在2026年第四季度前提交其治療斑禿的IND申請。雙特异性抗體候選藥物是一種新型雙特异性抗體，靶向核因子kappa-B配體受體激活因子(RANKL)及骨硬化蛋白，治療骨相關適應症。通過的內部體外及體內研究顯示，相較于市售批准的抗體（如地諾單抗及羅莫珠單抗），該候選藥物展現出更佳的療效。目前正在進行CMC優化，幷在非人靈長類動物中測試其毒性，幷計劃最早在2027年上半年前提交IND申請。協同推進戰略合作與BD授權，榮獲多項重磅榮譽公司于2025年8月與中山大學香港高等研究院有限公司（「SYSU-IAS」）簽訂全面戰略合作協議，本公司可直接使用SYSUIAS完備的實驗室設施與寶貴的數據資源，幷獲得包括靈長類及非靈長類實驗動物在內的科研資源支持，加速創新藥物研發進程，推動科研成果在全球範圍內向臨床應用轉化。同時公司正積極探索運用人工智能(AI)技術開展新靶點發現的可行性。2026年1月，公司受邀參加摩根大通醫療健康大會（JPM大會）幷與多家MNC、投資者分享了公司在自免領域的進展。依托雄厚的研發實力、豐富的管線儲備及精細化運營管理，公司于本年度榮獲多項重磅榮譽，包括粵港澳大灣區家族辦公室協會與香港國際家族辦公室協會聯合頒發的第二届「新質生産力企業大獎」，以及智通財經授予的「最具價值醫藥公司獎」。中國抗體董事長、執行董事兼首席執行官梁瑞安博士表示：「2025年，我們憑藉扎實的臨床數據證明了創新管線的全球競爭力，SM17在AD中的優异表現及其向IBD的拓展，標志著我們正從單一産品研發邁向平臺價值的持續兌現。展望2026年，生物醫藥行業正加速邁入『生物技術3.0時代』，創新驅動、多學科融合及全産業鏈智能化將成爲核心發展方向。我們將把握中國生物醫藥對外授權高速增長的歷史機遇，持續推進核心管線的臨床開發，深化國際合作布局。依托堅實的現金儲備、完善的産業鏈能力以及差异化創新優勢，爲股東創造長期價值，幷爲患者提供具有突破性的治療方案。」關于中國抗體製藥有限公司中國抗體製藥有限公司（股份代號：03681.HK）是首創新藥及潜在同類最佳抗體藥物研發領域的開拓者，專注于自身免疫性疾病、以及由此導致的神經系統疾病及其他難治的耗損性疾病，致力于解决未被滿足的醫療需求。中國抗體始終致力于開發針對全新靶點及通過創新機制的治療性抗體，旨在現有療法效果不佳的領域實現差异化臨床成果。其豐富的研發管線包括：SM17在AD治療中展現出卓越的止癢效果、皮膚清除率及安全性，同時在哮喘和特發性肺纖維化（IPF）領域具有應用潜力；其旗艦抗CD22舒西利單抗，除了臨床驗證對類風濕關節炎（RA）具有臨床療效外，目前正針對系統性紅斑狼瘡（SLE）和阿爾茨海默病開展臨床評估；另一款抗CGC（共同γ鏈）創新單抗，正準備進入治療斑禿和白癜風的臨床研究；中國抗體亦研發了一款能同時刺激骨胳生長及抑制骨胳流失、治療骨質疏鬆症的雙特异性抗體。中國抗體以突破性療效爲核心追求，不斷重新定義患者護理標準，穩居突破性療法領域的領軍地位。此新聞稿由真灼財經代中國抗體製藥有限公司發布投資者及媒體查詢聯絡人：Bunny LeeCitrus JiangWendy Huang電話：（852）5316 9995電郵：ir_sinomab@zhenzhuoglobal.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the year, loss for the year was approximately RMB105.0 million, decreased by RMB80.1 million from RMB185.1 million for the year ended 31 December 2024. The Company focused on SM17 Phase 1b clinical, transformation bridging study and preparation of Phase 2 clinical trial in 2025, of which the cost was less than large scale clinical studies in 2024. As at 31 December 2025, total funding available to use was approximately RMB351.5 million, representing a significant increase compared to RMB141.4 million as at 31 December 2024. During the year, the Group gained support from well-known institutional investors including Foresight, Fullgoal, and E Fund, completed two rounds of new share subscriptions under general mandate and successfully raised an aggregate amount of approximately HK$493.7 million in net proceeds. This drove net cash flows from financing activities for the Reporting Period to approximately RMB329.4 million, providing sufficient funding to support subsequent R&D and clinical advancement.SM17 Achieves Multiple BreakthroughsSM17 is a global first-in-class humanised monoclonal antibody (mAb) targeting the receptor for IL-25, which is capable of modulating Type II allergic reaction by targeting the receptor of a critical “alarmin” molecule interleukin-25 (IL-25). The compound has the potential for treating atopic dermatitis (AD), Inflammatory Bowel Disease (IBD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF).In the field of atopic dermatitis (AD), SM17 precisely targets upstream drivers of Type 2 immune responses by blocking IL-25, a key “alarmin” cytokine, thereby suppressing the inflammatory cascade at its source. While currently approved AD therapies, including biologics, can significantly improve Eczema Area and Severity Index (EASI) scores and patients’ quality of life, current drugs under development or on the market cannot simultaneously meet the clinical needs for rapid itch relief, skin lesion recovery, and good safety profiles, indicating substantial unmet market demand. SM17’s key innovation lies in its upstream modulation of the Th2 inflammatory cytokine pathway via IL-25 receptor inhibition, thereby suppressing multiple downstream pathogenic signaling pathways. Preclinical studies have demonstrated its potential for rapid itch relief, significant skin lesion recovery, and a favorable safety profile, directly addressing the key limitations of current therapies.In April 2025, SM17 achieved encouraging positive results in a Phase 1b study in China for the treatment of moderate to severe atopic dermatitis (AD): 12-week topline data after unblinding showed that in the high dose group, 91.7% of patients achieved pruritus relief (NRS-4), 75% achieved skin healing (EASI 75), and 41.7% achieved clear or almost clear signs of AD (IGA0/1). These results significantly outperform IL-4/IL-13 monoclonal antibodies and demonstrate a significantly better safety and tolerability profile than Janus Kinase inhibitors (JAK inhibitors), making SM17 potentially the first-in-class and best-in-class therapeutics which can simultaneously achieve rapid onset of action on pruritic relief, skin healing with a good safety profile. Study results of SM17 were published in various leading international journals. Phase 2 clinical trial for AD is expected to be entered into as early as mid-2026.On 11 December 2025, an Investigational New Drug application (“IND”) for SM17 in the indication of IBD was filed with and accepted by the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration of China (“NMPA”), and the IND was subsequently approved in February 2026. This IND submission represents an important step toward expanding SM17’s therapeutic scope beyond AD to IBD, including Crohn’s disease (“CD”) and ulcerative colitis (“UC”), which are chronic, debilitating conditions with significant unmet medical needs. In October 2025, the first cohort of healthy subjects was dosed in a Phase 1 bridging clinical trial for the route of administration conversion in China. As of 31 December 2025, a total of 30 healthy subjects had been enrolled and our follow-up visits for all healthy subjects were completed in February 2026. This bridging study is expected to be completed by the second quarter of 2026. Data from this study will be leveraged to support the progression of the IBD indication directly to Phase 2 clinical development.Early-Stage Pipelines Drive Continuous Innovation GrowthIn terms of early-stage pipeline development, the Company continues to make steady progress. In June 2025, Its partner, Everest Medicines, has announced positive results from the Phase Ib/IIa clinical trial of EVER001 (SinoMab’s SN1011) for the treatment of primary membranous nephropathy (PMN), further enhancing the commercial value of the pipeline.At the same time, multiple early-stage R&D programs are progressing steadily. Anti-CGC antibody is an in-house developed, first-in-class humanised anti-γc antibody. Our in vitro assays suggested that our antibody could suppress inflammation and autoimmunity driven B, T and NK cell activation. Animal studies demonstrated that our antibody could be a potential therapeutic agent for the treatment of vitiligo, alopecia areata and possibly other autoimmune diseases through the modulation of immune cell expansion, autoreactivity and tissue infiltration. We are currently in the process of CMC optimisation and toxicology studies for our antibody and plan to submit our IND application for the treatment of alopecia areata by the fourth quarter of 2026 at the earliest.Bispecific antibody candidate is a novel, bispecific antibody targeting Receptor activator of the nuclear factor kappa-B ligand (RANKL) and sclerostin for bone-related indications. bsAb processes differential mechanisms of action tailored for the treatment of osteoporosis. Our in-house in vitro and in vivo studies demonstrated our candidate to have enhanced efficacy over market-approved antibodies such as Denosumab and Romosozumab. We are currently in the process of optimising CMC and testing toxicity in non-human primates and plan to submit our IND application by the first half of 2027 at the earliest.Expanding Strategic Partnerships and Gaining Strong Industry RecognitionsIn August 2025, the Company entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Institute of Advanced Studies Hong Kong Limited (“SYSU-IAS”). Under the cooperation agreement, the Company enjoys direct access to SYSU-IAS’s comprehensive laboratory facilities and valuable data resources, as well as access to primate and non-primate animal studies supply resources, to accelerate the development of innovative drugs and promote the translation of scientific research into clinical applications worldwide. Furthermore, the Company is actively exploring the feasibility of using artificial intelligence (AI) technology for new target identification.In January 2026, the Company was invited to participate in the J.P. Morgan Healthcare Conference, where it shared its progress in the autoimmune field with multiple multinational pharmaceutical companies (MNCs) and investors.With the support of our strong R&D capabilities, extensive pipeline assets and refined operational management, we are thrilled to obtain renowned awards during the year, including the 2nd “New Quality Productive Forces Enterprise Award” jointly presented by the Greater Bay Area Family Office Association and the Hong Kong International Family Office Association, as well as the “Most Valuable Pharmaceutical Company Award” presented by Zhitong Finance.Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, comments: "In 2025, we demonstrated the global competitiveness of our innovative pipeline with solid clinical data. The outstanding performance of SM17 in AD and its indication expansion to IBD signify our continuous transition from single-product R&D to the realisation of platform value. Looking ahead to 2026, the biopharmaceutical industry has been accelerating into the “Biotech 3.0 Era”, which is characterised by innovation-driven development, multidisciplinary integration, and intelligent processes across the entire supply chain. We are well-positioned to capture the historic opportunity of the rapid growth of out-licensing deals in China’s biopharmaceutical industry, continue to advance the clinical development of our core pipelines, and deepen our international partnership footprint. Relying on our solid cash reserves, full-spectrum capabilities across the industry chain and the principle of differentiated innovation, we strive to maximize the returns of shareholders in the long run and provide life-changing breakthrough therapies for patients.”About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeCitrus JiangWendy HuangPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 這家承載356年品牌傳承的中醫醫療服務龍頭近日正在港股招股，背靠"老字號"，補齊了同仁堂集團"制藥-零售-醫養"大健康生態圈的最後一塊拼圖 。本次全球發售1.08億股，其中香港公開發售約10%，國際發售約90%。基石投資者已鎖定占發行規模逾46%，基石占比接近最高限額。機構真金白銀入場：基石比例高，機構參與熱度足數據是最誠實的信號。據招股書披露，基石投資者航空港科技資本（香港）及Aurora SF將按發售價認購總金額約3.89億港元的股份，占全球發售規模逾46%，這一比例在近期港股IPO中處於較高水平。基石鎖定比例高意味著上市後可流通籌碼有限，對二級市場價格支撐更強。此外，基石鎖定期超過傳統規定的6個月，進一步增強了市場的預期。獲客成本極低：僅為同行業的六十分之一在醫療服務行業，獲客成本是決定盈利天花板的關鍵變量。同仁堂醫養背靠始創於1669年的"同仁堂"金字招牌，品牌壁壘的經濟價值可以用一個數字概括：2024年推廣費占收入比例僅約0.2%。然而就診人次卻從2022年的132.1萬飆升至2024年的297.7萬，CAGR高達50.1%。2025年前9月達253.6萬，同比再增21.5%。會員從43.6萬增至76.7萬（2025年9月），複購粘性強勁。隨著收入規模擴大，同行需要花在營銷上的每一分錢，對同仁堂醫養而言幾乎都可以直接轉化為利潤。這是任何競爭對手都無法在短期內複制的護城河。盈利拐點已確立：經調整淨利潤增長29%對於處於上市窗口的成長型企業，投資者最關心的是：盈利趨勢是向上還是向下？答案很明確——向上，且加速。財務數據顯示，公司已展現出穩健的盈利能力。2022年至2024年，公司已由虧損923萬元轉為盈利4620萬元，經調整淨利潤達6173萬元，增長達到29%；毛利同期從1.43億元增至2.22億元，年複合增長率為 24.8%；2024年現金轉化率87.2%，有息債務占比僅11.56%，持有現金2.25億元，盈利質量顯著提升 。同仁堂醫養當前的發展階段與固生堂上市時高度相似，盈利能力剛進入釋放通道，增長最快的階段可能尚未到來。複制增長階段：計劃新增20家醫療機構中醫醫療服務是業績基本盤，公司已構建包含25家醫療機構的分級診療網絡，其中自有醫療機構12家，管理醫療機構12家，此外還有1家互聯網醫院提供線上診療服務。截至2024年就診人數約300萬人，CAGR高達50.12%；2025年前9月約253.6萬，同比再增21.5%；會員數量約74萬人，合作藥店約500餘家。作為同仁堂集團打開增長空間的核心業務，醫療服務板塊規模還需要更強力的支持與擴張。根據其募集資金使用披露，該公司計劃新收購5家醫療機構、以輕資產的方式新建5家醫療機構，並額外向5-10家醫療機構提供管理服務。可見，其未來快速擴張的戰略清晰，"收購+輕資產新建+管理輸出"三路徑協同。非"名醫驅動"：依靠標准化"體系驅動"對中醫醫療服務企業而言，最大的成長瓶頸在於"名醫能否複制"。同仁堂醫養正在用一套體系化的方法論回答這個問題。公司向上遊延伸，自建了供應鏈體系，完成了端到端的產業鏈閉環。除藥品外，健康產品銷售也實現了品牌價值的商業化變現。公司已獲授權在浙江省獨家銷售同仁堂爆款安宮牛黃丸系列產品，截至最後實際可行日期，公司已向超過4000家機構客戶銷售健康產品及其他產品。此外，公司將雲數字化系統紮根進網絡內每一家醫療機構，通過實時數據分析及管理，用智能系統代替"院長"，正在向"人機協作式"新型連鎖醫療管理方式過渡。讓增長不再完全依賴於個別名醫的"人治"，而是依托可複制的運營體系、數字化中臺和人才培養機制，實現規模化、標准化擴張。AI+中醫：醫藥數據壁壘深厚作為同仁堂集團在中醫服務領域唯一戰略性布局的載體，同仁堂醫養正站在傳統中醫與人工智能交匯的曆史拐點上 。同仁堂集團近期積極推動AI技術在中醫藥領域的落地應用，已與小米聯合打造"AI智能中醫藥健康服務智能體"，將傳統中醫智慧與現代AI技術深度融合，形成"咨詢—建議—服務—購藥"的服務閉環 。展望未來，萬億規模的中醫醫療服務市場正迎來龍頭整合的黃金窗口期。同仁堂醫養以多輪驅動的發展模式、穩健的財務基礎及AI技術的前瞻布局，不僅完成了老字號資本版圖的最後一塊"拼圖"，更開啟了中醫服務與前沿科技深度融合的新紀元。隨著上市募集資金的到位，相信同仁堂醫養有望加速推進核心業務的全面AI轉型，在萬億級中醫醫療服務市場中持續鞏固龍頭地位，引領行業邁向智能化新時代。轉載自格隆匯 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 中國領先的技術驅動移動出行平台嘀嗒出行（「嘀嗒」或「公司」，股票代碼：02559.HK）公佈了截至2025年12月31日止年度的經審計綜合年度業績。財務亮點：-截至2025年12月31日止年度，收入為人民幣5.02億元，2024年同期為7.87億元。-截至2025年12月31日止年度，毛利為人民幣3.33億元，2024年同期為5.67億元。-截至2025年12月31日止年度，淨利潤為人民幣1.30億元，2024年同期為10.04億元。-截至2025年12月31日止年度，經調整淨利潤（非國際財務報告準則計量）為人民幣1.38億元，而2024年同期為2.21億元。運營亮點：-截至2025年12月31日止年度，交易總額達人民幣47億元，訂單總數達到8090萬。-截至2025年12月31日，註冊用戶數超過4.15億。-截至2025年12月31日，認證私家車主數量達到約2100萬。業務展望：出行相關業務2025年是嘀嗒出行從專注于順風車的平台，向更為綜合的出行及車輛服務平台轉型的關鍵之年。2025年，嘀嗒出行推出了聚合打車業務，來進一步豐富平台的出行場景，使「中短途+立即出發」的即時出行需求與順風車「中長途+預約出行」的場景形成有效互補，增強用戶在不同出行決策場景下的選擇彈性。嘀嗒出行還開啟了二手車交易線索業務，拓展車輛全生命週期的業務範圍，並提升車主生態的用戶參與度。嘀嗒出行認為，順風車在中國仍處於早期發展階段，有潛在的巨大市場需求還未被充分釋放，而順風車的益處還未被完全認知。嘀嗒出行將持續致力於創新，圍繞平台的出行場景，繼續發展平台獨特的競爭優勢和價值，以更好地服務用戶群體。未來，嘀嗒出行計劃進一步發展聚合打車業務及其他出行相關服務，並持續擴展服務品類。有關嘀嗒出行截至2025年12月31日止年度全年業績公告的完整內容，請訪問：https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf關於嘀嗒出行嘀嗒出行（「嘀嗒」或「公司」，股票代碼：02559.HK）是中國領先的技術驅動型出行平台。公司通過提供順風車平台服務，為乘客和出行路線及時間相近的私家車主進行匹配，從而在不增加環境負擔的前提下創造了更多運力。公司還提供聚合打車服務，以滿足更多元的出行場景需求。嘀嗒出行致力於讓出行生態更綠色、更高效，讓每一次出行體驗溫暖而愉悅。前瞻性聲明本新聞稿包含有關公司業務前景、預測業務計劃和增長戰略的前瞻性陳述。這些前瞻性陳述基於公司目前信息，並基於本新聞稿發佈時的前景進行陳述。它們基於某些期望、假設和前提，其中一些是主觀的或不可控的，可能被證明是不正確的，未來可能無法實現。前瞻性陳述背後存在大量風險和不確定性。有關這些風險和不確定性的更多信息，請參閱公司網站上的其他公開披露文件。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 24, 2026 - (ACN Newswire via SeaPRwire.com) – Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK), a leading technology-driven mobility platform, announced the audited consolidated annual results for the year ended December 31, 2025.Financial Highlights:- Revenue was RMB502.4 million for the year ended December 31, 2025, compared to RMB787.2 million for the year ended December 31, 2024.- Gross profit was RMB332.9 million for the year ended December 31, 2025, compared to RMB567.0 million for year ended December 31, 2024.- Net profit was RMB129.8 million for the year ended December 31, 2025, compared to RMB1,004.3 million for the year ended December 31, 2024.- Adjusted net profit (non-IFRS measure) was RMB137.9 million for the year ended December 31, 2025, compared to RMB221.4 million for the year ended December 31, 2025.Operation Highlights:- Gross transaction value amounted to RMB4.7 billion and the total number of orders reached 80.9 million for the year ended December 31, 2025.- Registered users reached over 415 million as of December 31, 2025.- The number of certified private car owners reached approximately 21 million as of December 31, 2025.Business OutlookMobility-related business 2025 marked a pivotal year as the Company transitioned from a single-focus carpooling platform toward a more integrated mobility and vehicle services platform. In 2025, the Company launched ride-hailing aggregation platform services to diversify service offerings. Such services are intended to complement the carpooling business by addressing additional mobility scenarios, including short-to-medium distance and immediate travel needs, in addition to the medium-to-long distance and pre-arranged travel scenarios typically served by carpooling. The Company also commenced used car trading referral services to expand business scope along the vehicle ownership lifecycle and enhance engagement within the Company’s car owner ecosystem. The Company believes carpooling in China is still at its early stage of development, with significant market demand yet to be fully released and the benefits of carpooling not fully recognized by the public. The Company will remain committed to innovation as the Company continues to develop unique competitive strengths and value around mobility scenarios to better serve the user base. In the future, the Company plans to further develop ride-hailing aggregation platform services and other mobility-related services and to continue to expand service offerings.For the full announcement of Dida for the annual results ended December 31, 2025, please visit:https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf About Dida Inc.Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK) is a leading technology-driven mobility platform in China. The Company creates more transit capacity with less environmental impact by providing carpooling marketplace services to pair up riders with private car owners if they are heading in similar directions at compatible times. It also provides ride-hailing aggregation platform services to address additional mobility scenarios. Dida makes the mobility ecosystem greener and more efficient, and each trip experience warm and enjoyable.Forward-Looking StatementsThis press release contains forward-looking statements relating to the business outlook, forecast business plans and growth strategies of the Company. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond the control. These forward-looking statements may prove to be incorrect and may not be realized in future. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding these risks and uncertainties is included in the other public disclosure documents on the corporate website. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 3月20日，"同仁堂"旗下核心醫療平臺--北京同仁堂醫養投資股份有限公司，（簡稱"同仁堂醫養"）正式啟動香港公開發售，邁出登陸香港聯交所主板的關鍵一步。作為同仁堂集團唯一戰略聚焦於中醫服務的核心板塊，同仁堂醫養的此番亮相，不僅是一家企業的資本化進程，更標志著中國最具代表性的百年中醫品牌，正式將標准化"中醫診療"推向國際資本市場。根據招股文件，同仁堂醫養（股份代號：02667.HK）此次全球發售108,153,500股H股，其中香港公開發售占10,815,500股（可予重新分配），國際發售占97,338,000股。每手500股，入場費約為4,191.85港元，發售價範圍定於每股7.30港元至8.30港元，以發售價中位數7.80港元計算，經扣除相關費用後，集資淨額預計約為7.71億港元。中金公司擔任其獨家保薦人及獨家整體協調人，設置綠鞋。航空港科技資本、Aurora SF兩大基石投資者已提前鎖定46%份額，彰顯對公司長期價值的信心。百年品牌鑄就競爭壁壘，分級網絡構建服務版圖在中國醫療健康行業的眾多參與者中，同仁堂醫養擁有一項難以複制的核心資產--357年同仁堂品牌背書。招股書顯示，同仁堂醫養定位於同仁堂集團旗下專注於中醫醫療服務的戰略子公司，聚焦中醫醫療服務核心賽道，構建"醫養結合、線上線下一體化"的特色服務體系，業務涵蓋中醫醫療服務、機構管理服務、健康產品銷售三大核心板塊，形成多層次、全周期的健康服務供給。品牌壁壘的量化體現尤為突出。數據顯示，公司推廣費用率僅為0.2%，遠低於行業平均水平。與行業平均銷售費用率約為12%-13%相比，同仁堂醫養低於其約60倍。這一數據意味著，當同業仍在大規模投入營銷獲客時，同仁堂醫養的患者已憑品牌認知主動就診--這是百年老字號鑄就的天然流量入口，也是競爭對手無法在短期內複制的結構性優勢。中醫分級網絡仍為行業先鋒。在業務布局方面，同仁堂醫養已建成分級中醫醫療服務網絡，擁有12家自有線下醫療機構以及1 家互聯網醫院，同時向12 家公立線下醫療機構提供管理服務，覆蓋北京、浙江、上海、山西、貴州、遼寧、陝西等核心區域，形成"連鎖醫院-基層醫療機構-互聯網醫院"的三級架構，實現了全國服務網絡的高效協同。其中，連鎖醫院承擔疑難重症的多學科診療職能，基層醫療機構（門診部、診所、社區醫院）負責常見病、慢病管理和日常健康維護，互聯網醫院則打破時空限制，將服務半徑延伸至全國。三級架構分層協同、高效配置醫療資源，為後續全國化擴張奠定了可複制的基礎模型。品牌及網絡效能持續高速釋放。數據顯示，2024年其網絡內總就診人次達297.7萬，2022年至2024年的複合年增長率高達51.9%。會員數量從43.6萬人增至76.7萬人，客戶黏性與複購率穩步提升。旗下醫療機構實現醫保定點全覆蓋，患者就醫便利性與支付可及性得到有力保障。多輪驅動式外延擴張，整合賦能標准化連鎖本次 IPO 核心看點，在於同仁堂醫養以"戰略性並購、輕資產新建及管理服務輸出"三種方式實現規模與質量雙躍升。公司立足百年品牌勢能，采取"網絡整合+標杆管理+全國複制"的擴張路徑，精准卡位區域優質中醫機構，快速補齊網絡、專科、客流與供應鏈全鏈路。2022年公司完成對浙江三溪堂保健院、三溪堂國藥館的控股收購，一舉拿下浙江區域安宮牛黃丸系列獨家經銷權，打通醫療服務與健康產品協同變現通道；2024年相繼收購上海承志堂等醫療機構控股權，強勢切入長三角核心市場，實現京滬浙多點聯動。衡量一家連鎖醫療企業並購戰略成敗的關鍵，不在於"買了多少"，而在於"整合得多好"。同仁堂醫養依托采購協同平臺、雲HIS與BIS數字化系統，對收購機構實施醫療質量、運營效率、成本管控一體化管理，推動被投機構快速融入同仁堂體系、釋放盈利潛力。與此同時，公司的管理服務毛利率超70%，與高毛利健康產品、穩定醫療服務業務形成互補，構建韌性極強的盈利結構。同仁堂醫養並非傳統的重資產醫院集團，而是走出一條"輕資產管理式"醫療集團路徑，為未來規模化擴張提供了更具彈性的增長空間。基本面穩定有韌性，行業打開增長空間財務表現也印證同仁堂醫養的發展模式。2022-2024年，公司營收從9.11億元增至11.75億元，收入CAGR達13.6%，毛利潤CAGR更高達24.8%；2024年淨利潤4620萬元、經調整淨利潤6173萬元，同比增長29.0%，呈現"增收更增利"的高質量增長特征。期間費用率從2022年的17.1%下降至2025年前三季度的13.6%，下降3.5個百分點，標准化運營和數智化轉型的效率紅利持續釋放。經營性現金流轉化率達87.2%，賬面現金2.25億元，利息覆蓋充裕，財務安全邊際充足。企業正在從"規模擴張期"平穩過渡至"利潤釋放期"--這正是連鎖醫療企業盈利質量躍升的關鍵階段。從行業趨勢來看，中醫醫療服務正處於政策驅動與需求擴容的雙重紅利期。據弗若斯特沙利文數據，中國中醫醫療服務市場規模預計2029年將達1.62萬億元，2024年至2029年CAGR為9.9%。在人口老齡化持續深化和"全民養生"消費趨勢下，中醫醫養賽道的確定性增長邏輯清晰。此外，在中醫藥振興政策與人口老齡化需求雙重驅動下，中醫醫療服務行業進入整合提速期。同仁堂醫養憑借品牌壁壘、並購整合能力、標准化複制體系三大核心優勢，在行業集中度提升過程中占據主動。本次IPO募集資金將重點投向醫療網絡擴張、服務能力升級等。同仁堂醫養以資本為翼，以醫養為本，將百年民族品牌底蘊轉化為現代醫療服務競爭力。此次港股上市，不僅打開全國化擴張空間，更為投資者分享中醫醫養黃金賽道紅利，領航中醫藥醫療服務行業高質量發展新征程。轉載自中國證券報 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - On March 23, 2026, Tingyi (Cayman Islands) Holding Corp. (0322.HK, the “Company”, together with its subsidiaries, the “Group”) is pleased to announce its 2025 annual results. In 2025, amid drastic changes in consumer behaviours and a complex market environment, the Group remained firmly committed to the consumer-centric approach, advanced the high-quality development in a coordinated manner, promoted product innovation and upgrades to precisely meet the demands of diverse scenario-based needs, while accelerating the expansion into high-growth channels. It comprehensively improved overall operational efficiency and drove steady growth of all key financial indicators. For the twelve months ended on December 31, the Group’s revenue decreased by 2.0% year-on-year to RMB 79.068 billion. Among which, the revenue from the Instant Noodles Business was RMB28.421 billion, while the revenue from the Beverages Business was RMB50.123 billion. The gross profit margin grew 1.7 percentage points to 34.8% year-on-year, EBITDA increased by 10.2% year-on-year to RMB 10.607 billion. The profit attributable to shareholders of the Company increased significantly by 20.5% year-on-year to RMB4.501 billion. The directors recommended the payment of a final dividend and a special final dividend of RMB39.92 cents and RMB39.92 cents per ordinary share respectively. Dividend payout ratio for the year remained at 100%.Financial Summary For the twelve months ended 31 December RMB’00020252024ChangeRevenue79,068,02280,650,914↓ 2.0%Gross margin34.8%33.1%↑ 1.7ppt.Gross profit of the Group27,531,70426,695,643↑ 3.1%EBITDA10,606,5229,627,802↑ 10.2%Profit for the period5,175,8524,322,135↑ 19.8%Profit attributable to owners of the Company4,500,6983,734,429↑ 20.5%Earnings per share (RMB cents) Basic79.8666.28↑ 13.58 centsDiluted79.8466.28↑ 13.56 centsAs at 31 December 2025, cash at bank and on hand (including long-term time deposits) was RMB19,486.056 million, representing an increase of RMB3,483.388 million when compared to 31 December 2024. Gearing ratio was -29.8%.In 2025, China's economy demonstrated resilience with a 5% year-on-year GDP growth. However, the food and beverage market entered into the stage of stock competition and demand upgrading for functional and emotional values. Brand, quality, and flavors remained key drivers of purchasing decisions. Additionally, emerging formats such as instant retail, snack discount stores, and membership stores had brought about drastic changes in channels and consumer behaviors. Against the backdrop of intensifying market competition and evolving consumption patterns, a company's core competitiveness increasingly lies in building a strong moat for their core brands. Those that continuously drive product innovation and channel optimization around consumer needs will be more agile in capturing market opportunities, strengthening consumer trust, and ultimately achieving high-quality and sustainable long-term development.In 2025, the gross profit of the Instant Noodles business improved steadily. The Group’s revenue from the Instant Noodles Business was RMB28.421 billion, which grew slightly year-on-year, accounting for 35.9% of the Group’s total revenue. During the year, due to favorable raw material prices and selling prices, the gross profit margin of instant noodles expanded by 1.1 percentage points year-on-year to 29.7%, and the profit attributable to shareholders of the Company for the year of 2025 in the Instant Noodles Business increased significantly by 10.1% year-on-year to RMB 2.252 billion, driven by the year-on-year increase in gross profit margin. During the year, in the face of intensifying industry competition, the Instant Noodles Business steadily advanced its core strategy of “consolidating blockbuster products, seizing the popular flavors track, and cultivating innovative products.” By continuously improving the product portfolio and forging deep collaborations with popular IPs, it effectively amplified brand presence and steadily optimized gross margin structure. On the product front, the business relied on deep cultivation of core blockbuster products and iterative flavor upgrades, while closely aligning with evolving consumer trends to precisely target the health-focused and premium market segments, tapping into new growth opportunities. On the marketing front, it leveraged mainstream social platforms such as Bilibili and Xiaohongshu to conduct omnichannel communication, combined with cross-industry collaborations with well-known IPs to reinforce the brand perception of high-end and convenient consumption. As a result, brand influence and market recognition improved significantly. Meanwhile, guided by aerospace-grade quality standards, the business promoted the full application of aerospace patented temperature control technology in the production line, fully demonstrating the brand’s differentiated advantages in product quality and technological innovation.The Beverages Business firmly executed the strategy of “consolidating core products and developing innovative products”, the revenue from the Beverages Business was RMB50.123 billion, accounting for 63.4% of the Group’s total revenue. During the year, due to favorable raw material prices and optimized product mix, the gross profit margin of Beverages expanded by 2.2 percentage points year on-year to 37.5%. Driven by a year-on-year expansion of gross profit margin, the profit attributable to shareholders of the Company in the Beverages Business for the year of 2025 increased significantly by 18.5% year-on-year to RMB 2.274 billion. During the year, the Beverages Business strengthened its core category advantages and proactively positioned itself in emerging tracks, establishing a collaborative growth model across the full product portfolio. On the product front, while consolidating core products, it continuously expanded into incremental growth segments by launching high-quality sugar-free offerings and aligning with the wellness consumption trend to create herbal wellness scenarios, successfully opening up new growth spaces such as products made from homologous medicinal and food materials. On the marketing front, the Company deepened IP collaborations to broaden audience reach, enhanced its presence in cultural tourism channels and high-end hotel partnerships, and targeted premium consumption scenarios. These efforts consistently elevated brand value, providing strong support for the business to achieve steady operations and sustainable growth.Mr. Wei Hong-Chen, Chief Executive Officer, commented, “As the first year of the 15th Five-Year Plan period, 2026 is expected to see expanding domestic demand become a key driver of economic growth under a more proactive and effective macroeconomic policy, while the consumer market will also usher in a critical window of profound transformation. The food and beverage industry will closely follow the theme of high-quality development, and consumption stratification will become more refined. Functional attributes, emotional resonance, and green concepts are shifting from trends to mainstream factors, becoming core elements driving brand growth. In the face of opportunities and challenges in the new cycle, the Group will be guided by the spirit of “Back to Day 1” as its strategic direction, embracing the efficiency, agility and entrepreneurial drive of our founding days, and building a platform that encourages honesty, bold experimentation and mutual growth, thus fully unleashing the vitality of all employees. While unleashing organizational vitality, we will continue to strengthen our foundational R&D capabilities and digital operation systems. Rooted in the health needs of the nation, we will drive product iteration and upgrades through technological innovation, continuously elevate product value, and align high-quality supply with the evolving consumption landscape. Adhering to the “economic-ESG” sustainable development philosophy, we will internalize social responsibility as the foundation of our development, solidify user trust through quality products, build a brand moat with long-term value, and create a sustainable and stable return system for shareholders, propelling the Group toward steady and sustained progress in the new stage of high-quality development.”About Tingyi (Cayman Islands) Holding Corp. (0322.HK)Tingyi (Cayman Islands) Holding Corp. (the “Company”), and its subsidiaries (the “Group”) specialise in the production and distribution of instant noodles and beverages in the People’s Republic of China (the “PRC”). The Group started its instant noodle business in 1992, and expanded into instant food business and beverage business in 1996. In March 2012, the Group further expanded its beverage business by forming a strategic alliance with PepsiCo for the beverage business in the PRC. The Company exclusively manufactures, bottles, packages, distributes and sells PepsiCo soft drinks in the PRC. After years of hard work and accumulation, “Master Kong” has become one of the best-known brands among consumers in the PRC.For enquiries, please contact:Investor EnquiriesInvestor Relations Team, Tingyi (Cayman Islands) Holding Corp.E-mail: ir@tingyi.comChristensen China LimitedStephanie ChenE-mail: stephanie.chen@christensencomms.comTel: +852 2117 0861 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 2026年3月23日，康師傅控股有限公司（0322.HK，以下簡稱「公司」，連同其附屬公司「集團」）發佈2025年年度業績公告。2025年，在消費行為劇烈變革與市場環境複雜多變的背景下，本集團始終堅持以消費者為中心，統籌推進高質量發展，推動產品創新升級，精准滿足多元場景需求，同時加速開拓高增長渠道，全面提升整體運營效能，推動各項財務指標穩健發展。截至2025年12月31日止十二個月，集團收益同比衰退2.0%至790.68億人民幣。其中，方便面事業收益284.21億人民幣，飲品事業收益為501.23億人民幣。毛利率同比提高1.7個百分點至34.8%，EBITDA同比增長10.2%至106.07億人民幣，本公司股東應佔溢利同比成長20.5%至45.01億人民幣。董事會建議派發末期股息每股普通股人民幣39.92分及特別末期股息每股普通股人民幣39.92分，全年派息率達100%。財務摘要 截至12月31日止12個月 人民幣千元2025年2024年變動收益79,068,02280,650,914↓ 2.0%毛利率（%）34.8%33.1%↑ 1.7個百分點集團毛利27,531,70426,695,643↑ 3.1%扣除利息、稅項、折舊及攤銷前盈利（EBITDA）10,606,5229,627,802↑ 10.2%本期溢利5,175,8524,322,135↑ 19.8%本公司股東應占溢利4,500,6983,734,429↑ 20.5%每股溢利（人民幣分） 基本79.8666.28↑ 13.58分攤薄79.8466.28↑ 13.56分於2025年12月31日之銀行存款及現金（含長期定期存款）為人民幣19,486,056千元，相較2024年12月31日增加人民幣3,483,388千元，淨負債與資本比率為-29.8%。2025年，中國經濟在GDP同比5%的增長中展現韌性。但食品飲料市場進入存量博弈，以及對功能價值與情緒價值需求升級階段。品牌、品質與風味仍是購買決策的重要驅動因素。此外，即時零售、零食折扣店、會員店等新興業態帶來渠道與消費行為劇烈變革。在市場競爭日趨激烈、消費行為持續演變的背景下，企業的核心競爭力愈發體現在核心品牌的護城河建設。能夠圍繞消費者需求，持續推動產品創新與渠道優化的企業，將更敏捷地捕捉市場機遇，鞏固消費者信任，進而實現高質量、可持續的長遠發展。2025年，方便面事業的毛利結構持續改善。方便面事業收益為284.21億人民幣，同比微幅增長，占集團總收益35.9%。年內，因原材料價格及售價有利，使方便面毛利率同比提高1.1個百分點至29.7%，由於毛利率同比提高帶動，令方便面事業2025年全年的本公司股東應占溢利同比大幅增長10.1%至22.52億人民幣。年內，面對日趨激烈的行業競爭，方便面業務扎實推進「鞏固大單品、佔領大口味賽道、培育創新產品」的核心戰略，通過持續完善產品矩陣，與熱門IP深度聯動，有效放大品牌聲量，穩步優化毛利結構。產品端，依託核心大單品深耕與口味迭代升級，同時緊密貼合消費趨勢變化，精准佈局健康化、高端化賽道，精准切入新增量市場。營銷端，依託B站、小紅書等主流社交平台開展全域傳播，疊加知名IP跨界合作，深化高端便捷的品牌認知，品牌影響力與市場認知度顯著提升。同時，以航天品質為引領，推動航天專利溫控技術在生產線全面落地應用，充分彰顯品牌在產品品質與科技含量的差異化優勢。飲品事業堅定實施「鞏固核心單品、發展創新產品」戰略。飲品事業整體收益為501.23億人民幣，占集團總收益63.4%。年內，因原材料價格有利及產品組合優化，使飲品毛利率同比提高2.2個百分點至37.5%。由於毛利率同比提高帶動，令飲品事業2025年全年本公司股東應占溢利同比大幅提高18.5%至22.74億人民幣。年內，飲品事業通過深化核心品類優勢與前瞻性佈局新興賽道，構建全品類協同增長格局。產品端，在穩固核心單品的基礎上，持續拓展增量賽道，推出高品質無糖產品，並緊扣養生消費趨勢，打造草本養生場景，成功開闢藥食同源等新增量空間。營銷端則持續強化IP深度合作拓寬受眾圈層，同時強化文旅渠道佈局及高端酒店合作，錨定高端消費場景，持續提升品牌價值，為業務實現穩健經營與可持續增長提供有力支撐。康師傅首席執行官魏宏丞先生表示：「2026年作為「十五五」開局之年，預計在更加積極有為的宏觀政策下，擴大內需將成為經濟增長的關鍵著力點，消費市場也將隨之迎來深度變革的關鍵窗口。食品飲料行業圍繞高質量發展主線持續演進，消費分層愈加精細，功能價值、情緒共鳴與綠色理念正從趨勢走向主流，成為驅動品牌增長的核心要素。面對新週期中的機遇與挑戰，集團將以「Back to Day 1」的精神為戰略引領，回歸創業初期的高效敏捷與狼性拼搏文化，打造敢講真話、勇於嘗試、共同成長的平台，充分激發全員活力。在釋放組織活力的同時，我們將持續夯實基礎研發能力與數字化運營體系，立足國民健康訴求，以科技創新驅動產品迭代升級，推動產品價值不斷躍遷，以高品質供給適配新消費結構。秉持「economic-ESG」可持續發展理念，我們將社會責任內化為發展底色，通過優質產品夯實用戶信賴，以長期價值構建品牌護城河，為股東打造可持續的穩健回報體系，推動集團在高質量發展新階段行穩致遠。」關於康師傅控股有限公司(0322.HK)康師傅控股有限公司（「本公司」）及其附屬公司（「本集團」）主要在中國從事生產和銷售方便面及飲品。本集團於1992年開始生產方便面，並自1996年起擴大事業至方便食品及飲品；2012年3月，本集團進一步拓展飲料事業範圍，完成與PepsiCo中國飲料事業之戰略聯盟，開始獨家負責制造、灌裝、包裝、銷售及分銷PepsiCo於中國的非酒精飲料。「康師傅」作為中國家喻戶曉的品牌，經過多年的耕耘與積累，深受中國消費者喜愛和支持。如有垂詢，請聯絡：投資者查詢康師傅控股有限公司投資者關係團隊電郵：ir@tingyi.com匯思訊中國有限公司陳敏芝電郵：stephanie.chen@christensencomms.com電話：+852 2117 0861 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亞太商訊 via SeaPRwire.com) - 3月23日，麥迪衛康正式發佈2025年度業績公告。數據顯示，公司年內溢利約人民幣698萬元，盈利能力顯著修復，全年扭虧為盈，經營性現金流狀況持續好轉。業績改善主要得益于“AI+數字化”帶動核心主營業務持續穩健增長，疊加公司聚焦高毛利優質項目，有效帶動整體毛利水平顯著提升。此次公司財務表現展現出強勁的修復彈性，是公司發展歷程中的重要里程碑。一方面，標誌著公司聚焦主業、優化業務結構的戰略取得實質性成效，經營質量與盈利能力邁入全新階段，為後續穩健發展築牢財務根基；另一方面，充分印證公司核心業務具備強勁增長韌性與市場競爭力，高毛利項目佈局持續釋放效益，也為公司深化醫療健康服務佈局、拓展優質業務版圖注入更強信心，進一步鞏固行業競爭力與可持續發展能力。3C服務體系覆蓋全產業鏈 技術創新構築核心競爭力經營效率的跨越式進步，離不開公司清晰的業務佈局與精准的戰略定位。在業務佈局方面，麥迪衛康以創新數字醫療服務提供商為定位，打造獨具競爭力的「3C服務體系」，涵蓋專業醫學內容服務（Content）、高端學術會議服務（Conference）、企業市場推廣服務（Corporation）三大核心領域，形成了覆蓋醫療全產業鏈的服務閉環，為業務高質量發展筑牢根基。2025年，公司數字化醫學平台的運營步入高質量發展的新階段。該平台不僅實現了專業醫療群體的高密度覆蓋，更在海量的學術交流與衛教傳播中，構築起一套精準、專業且具備高度粘性的知識服務體系。這種深度的數字化轉型，不僅顯著提升了醫學內容的傳播效能與學術影響力，更在賦能醫生臨床決策、助力健康知識普及方面發揮了關鍵作用，轉化為推動行業進步的實質性力量，進一步鞏固了公司在數字醫療生態中的引領地位。持續的技術創新，是驅動麥迪衛康高質量增長的核心引擎。在技術研發領域，公司擁有多項軟件著作權與發明專利，自主研發的「長頸鹿」系列數智平台已吸引數十萬名醫生入駐，顯著提升醫療服務與運營管理效率。2024年，公司持續深化AIGC場景落地，創新推出「AI智能體+醫生眾創」模式，助力醫生回歸高價值診療與科研工作；同時依託區塊鏈技術成功獲得數據服務商資質，實現醫學內容確權與授權運營，為醫療數字化生態建設樹立行業標杆。2025年，公司深入推進AI智能體的研發與場景應用探索，致力於與醫療專業人士協同，打造「AI+人工」深度融合的醫學內容數據標註及版權內容生產體系，並與數字資產交易平台業務形成有機銜接。此外，依托专病管理AI智能体所取得的阶段性突破，公司正进一步将数智化能力向产业上下游延伸，前瞻性地探索智能专病机器人赛道；同时，通过对柏慧康生物的战略投资，公司正积极探索在多组学创新检测领域的落地应用并已取得阶段性进展，借此构建起立体化的医疗创新服务网络。全國服務網絡縱深覆蓋 打開長期價值成長空間依託成熟的業務體系與核心技術支撐，麥迪衛康已搭建起覆蓋全國的專業服務網絡。目前，公司在全國設立近10家經營機構，重點佈局北京、上海、南京等核心醫療樞紐城市，服務合作三級醫療機構超3000家，其中包括北京天壇醫院、阜外醫院等國內頂尖三甲醫院。同時，公司深度參與卒中中心、胸痛中心等重點專科建設，構建起縱向貫通、橫向協同的全域專科醫療服務體系，為業務高效落地與市場持續拓展提供了堅實保障。廣泛覆蓋的服務網絡與專業高效的服務能力，讓麥迪衛康積累起優質且多元的客戶群體，行業龍頭地位持續鞏固。在數字醫療領域，公司自有互聯網醫療平台已匯聚註冊醫生超5萬名、註冊患者近36萬人次，2025年線上諮詢量突破50萬次，同比增長超19%，實現優質醫療資源高效觸達，有效緩解醫療資源分配不均難題。從行業發展趨勢來看，在人口老齡化加劇、慢性病管理需求攀升、政策持續賦能及AI數字技術深度滲透等多重驅動下，中國數字醫療產業正迎來黃金髮展期，據中商產業研究院數據預測，2025年中國數字醫療市場規模預計達5800億元，2031年突破1.2萬億元，廣闊的市場增量為麥迪衛康這類具備核心技術壁壘與全鏈條佈局的領軍企業，提供了持續成長與價值釋放空間。麥迪衛康以「3C服務體系」為基座，以技術創新與服務升級為引擎，憑藉覆蓋全國的服務網絡、廣泛優質的客戶資源以及前瞻性的戰略佈局，在行業內構建了獨特的競爭優勢與地位。未來，隨著數字醫療產業的持續升溫與公司業務的不斷深化，公司將緊抓醫療智能化轉型的時代機遇，聚焦AI小模型賦能，全面拓展業務版圖，夯實「AI+區塊鏈」技術底座，探索搭建全流程智能閉環體系。同時以「醫學專業服務+數字化技術」雙輪驅動，持續拓寬業務邊界、優化內部運營效能，在數字醫療賽道上實現更高質量的發展，打開廣闊成長空間。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Sydney, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - The International Career Institute (ICI) is marking its 20th anniversary with the launch of 100 scholarships, in a milestone initiative designed to widen access to flexible, career-focused online study. The scholarship announcement comes as more students look for practical ways to upskill, change careers or strengthen their professional credentials without putting work or family life on hold.New scholarships launched as International Career Institute celebrates two decades of career-focused educationTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10373/288837_60f2135b4402f876_001full.jpgOver the past two decades, the International Career Institute has built its reputation as an independent private provider of online education focused on practical, job-relevant learning. ICI offers 57 courses, has supported 58,453 students, and has learners in 191 countries, reflecting a substantial international footprint.The anniversary scholarship campaign is intended to do more than mark a birthday. It reflects a wider shift in the education market, where students are increasingly prioritising flexibility, affordability and direct career outcomes. ICI positions itself around exactly those needs: online delivery, self-paced study, personal tutor support, included course materials, flexible payment plans and career services aimed at helping graduates move into employment or advance in their chosen field.Applicants for the Leadership Scholarships are asked to demonstrate leadership potential or current leadership responsibilities and to complete an application process that outlines their background and motivation for study. Applicants facing financial disadvantage will be given priority. The scholarship forms part of a broader ICI scholarship offering and positions the initiative as a way to recognise leadership and help recipients take the next step in their development.For many adult learners, flexibility is not simply an added benefit; it is the condition that makes study possible. At the International Career Institute, students can study at their own pace, with no classes to attend and no additional textbooks or materials to purchase. Its online study model is structured around module-based written assessments rather than traditional exams, while students receive guidance and feedback from personal tutors throughout the course.Dr Michael Machica, Director of the International Career Institute, said the anniversary was both a celebration of the institution's history and a statement of intent for its future."Reaching 20 years is a proud milestone for the International Career Institute and a moment to reflect on how education has changed. From the beginning, our goal has been to make career-focused learning more flexible, more practical and more accessible for people whose lives do not fit the traditional study model. Over the next 20 years, we see ICI continuing to expand its reach, strengthen its industry relevance and help even more learners build meaningful careers through online education that works in the real world."That long-term focus on accessibility and employability remains central to the International Career Institute brand. Central to ICI's offering is tutor support, affordable pricing, interest-free payment plans, included materials and graduate career services. Those services include assistance with resumes, job searches, cover letters and interview preparation - features that help distinguish ICI in a competitive online learning market where students are increasingly outcome-focused.ICI's programmes are developed in consultation with industry experts and aligned with real-world job opportunities. That proposition - flexible study paired with career relevance - has become increasingly important as more learners seek education that fits around existing work, business, or family commitments while still contributing to employability and advancement.The release of 100 scholarships also gives the anniversary a broader public-interest dimension. In a cost-conscious environment, even motivated learners can hesitate when considering professional study. By offering scholarships focused on leadership and development, ICI is positioning its 20th anniversary not simply as a milestone but as an opportunity to invest in the next generation of professionals and career changers.Prospective students can explore scholarship eligibility, course options and the International Career Institute online study model through the institute's website, where they can also view course pages, student reviews and information about graduate support. For those considering a career change, promotion pathway or a more flexible way to formalise their skills, the anniversary scholarships create a timely reason to act.About International Career InstituteICI is an independent private provider of online education and training established in 2006. It offers career- and lifestyle-focused courses through a fully online, self-paced study model supported by personal tutors and graduate career services.Media ContactFor media enquiries, please contact:Email: info@ici.net.au Website: www.ici.net.auInternational Career InstituteTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10373/288837_60f2135b4402f876_002full.jpgTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/288837 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com